Top 50 Biotech Startup Investors in United Kingdom in February 2025

Investor	Biotech United Kingdom investments
UK Innovation & Science Seed Fund	57
Parkwalk Advisors	43
Scottish Enterprise	40
Oxford Science Enterprises	38
SOSV	37
Oxford Technology Management	35
Oxford Capital	33
Scottish Investment Bank	32
Jonathan Milner	31
Catapult Ventures	31
Oxford Science Enterprises	26
Mercia Fund Managers	25
Development Bank of Wales	23
Future Planet Capital	22
Epidarex Capital	22
Archangels	21
IP Group	20
AlbionVC	20
Newable Private Investing	20
Deepbridge Capital	19
Sofinnova Partners	18
GM&C Life Sciences Fund	18
Octopus Ventures	17
TRICAPITAL	16
Cambridge Angels group	16
Syncona Partners LLP	16
O2h Ventures	16
Northstar Ventures	16
Kelvin Capital	16
Hoxton Ventures	15
SFC Capital	15
Par Equity	15
Wren Capital	14
Calculus Capital	14
Business Growth Fund	14
Nesta Ventures	13
Cambridge Innovation Capital	13
24 Haymarket	13
M Ventures	13
Kindred Capital	12
Mercia Asset Management	12
IQ Capital	12
Wellcome Trust	12
YFM Equity Partners	12
Amadeus Capital Partners	11
Meltwind Advisory	11
Longwall Venture	11
SR One	11
Esperante Ventures	10
Dementia Discovery Fund	10

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Antiverse — Designing biologics for 100 challenging targets
iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
illumion — Illumion develops high-throughput optical tools to accelerate battery material development

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

Sisaltech — Sisaltech a natural fiber from the Agave plant, is durable, biodegradable, and has low environmental impact in production. Sisaltech makes the use of these in building insulation a very eco-friendly choice.
Kaly Group — KALY is like an intriguing group based on the description, it appears to be a collective of individuals with diverse interests and passions—innovators, sailors, and nature enthusiasts—coming together with a shared mission of exploration and discovery.
Scotmas Group — Scotmas are specialists in Chlorine Dioxide (ClO2) generators & dosing systems for drinking water treatment, Legionella control and SWRO.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

OxCan — Enabling curative cancer treatment through early detection
CryoLogyx — Assay Ready Cells - Discover CryoLogyx's advanced cryopreservation solutions, optimized for cell-based assays in drug discovery. Simply thaw with cell culture medium, and they are ready for use within 24 hours post-thaw.
Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Egregious — Egregious is an advanced research & intelligence lab established to defend humans from AI and provides narrative intelligence solutions across the public and private sectors to protect organisations and online users from malign influence using AI-driven data acquisition, insights, and engagement.
Arcube — We make sure all travellers, frequent and infrequent, make the most of travel loyalty programs, using our data-driven approach, airlines can understand their customers and provide hyper-personalised offerings to boost value and retention.Arcube uses a data-driven approach to make the most of airline loyalty programs for both frequent andinfrequent flyers. Our software allows airlines to understand their customers and provide hyper-personalised offerings to boost value and retention at no extra cost to the airline.
FinCrime Dynamics — Our mission is to help make the world’s financial system safer through rapid deployment of effective AI for financial crime analytics, enabled by enriched synthetic data that captures the dynamics of fraud and money laundering and loads them into tailor-made scenarios that explore diverse threats that financial organisations are exposed to.Thisgoal has taken us to the forefront of Synthetic Data and Fincrime Analytics, and we are proud to have in our team people that have helped shape the state-of-the-art of these fields.Keywords: Finacial services, AML, Synthetic Data, Fintech, Machine learning, Big data, Simulation, Fraud Analytics, Compliance

Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Canada

Portfolio highlights

Quibim — Leading radiomics company pioneering quantitative imaging biomarkers and medical applications in precision medicine.
Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.
Exciting Instruments — Exciting Instruments Limited is a joint company founded in Sheffield that combines the software prowess of Bulldozer Limited with Dr. Timothy Craggs' knowledge of single molecules. Through the use of cloud connectivity and real-time data visualisation, we are a genuine science and software partnership on a mission to assist you in streamliningthe procedure for creating discoveries in biophysics, life sciences, drug discovery, and medical diagnostics.

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Seed, Series A
United Kingdom, United States, Israel

Portfolio highlights

Path Robotics — We create manufacturing robots that autonomously scan, position, and weld your parts without the need for skilled welders or robot programmers.
Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

Amped PCR — At Amped PCR, we empower life science researchers and scientists with our high-performance diagnostic technologies. We specialise in advanced Polymerase Chain Reaction (PCR) technology, providing robust diagnostic tools tailored to the life sciences and for critical sectors such as food safety, en
Coffi Lab — Dog friendly independent coffee shops, inspired by our love of coffee & labs. In Monmouth, Marlborough & Abergavenny. Proud Supporter of Guide Dogs UK.
Stable Resources — We are Stable. We pioneer new ways for teams to collaborate and innovate with technology being the enabler.

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Convertible Note
United Kingdom, United States, Canada

Portfolio highlights

Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Antiverse — Designing biologics for 100 challenging targets
Wittaya Aqua — A better approach to aquaculture management

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investment focus

Health Care, Biotechnology, Therapeutics
Seed, Series A, Series B
United Kingdom, United States, Australia

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
Alesi Surgical — Developer of Ultravision, the revolutionary system that clears surgical smoke from the visual field during laparoscopic surgery

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.

Investment focus

Software, Health Care, Information Technology
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
IONATE — IONATE Ltd. is a technology company developing next-generation Hybrid Intelligent Transformers.
Infact Systems — Infact Systems is a company that focuses on bringing affordability and credit information into the 21st century. They facilitate the sharing of real-time, contextual data, primarily in the banking industry. Their mission is to increase responsible financial behavior by providing real-time data for modern credit. They offer integration andcustomization services for HPZone, particularly in terms of connecting with external laboratory systems. Infact Systems also provides services to help women take control of their finances.

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Berry Street — Nutrition therapy by registered dietitians covered by insurance.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.

Investment focus

Software, Health Care, Information Technology
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Amplience — The shopping experience platform for generating, creating and delivering content with context
Orbex Space — Founded in 2015, Orbex is Europe’s leading private launch services company, focused entirely on supporting the needs of the small satellite industry.Orbex has developed one of the most advanced, low carbon, high performance micro-launch vehicles in the world. They launch customer satellites into polar and sun-synchronous low Earth orbits from aunique, modern launch location in the heart of the European continent.They offer a flexible core launch service and a wide suite of supporting services that make life easier for customers. Their European location means shorter supply lines, easier communications and reduced operational costs. Their advanced launch vehicle means higher reliability, more flexible mission profiles and a regular, scheduled launch service.
ThreatMark — ThreatMark is the future of trust in the digital world. The company was founded with a vision of bringing trust to interactions across all digital channels through profound cyber security know-how and latest advancements in AI & Data Analytics. ThreatMark processes a comprehensive set of data inputs to continuously validate user’s identity& their intentions while protecting the user’s most valuable assets.At ThreatMark, we make sure that the entire digital journey (onboarding, authentication, account management, transactions…) is trusted and safe for both end-users and businesses. Major banks use ThreatMark’s deep behavioral profiling engine to analyze vast numbers of user specific data & behavioral traits to precisely identify legitimate users and deny fraudsters in real-time. For banks and their users, ThreatMark enables seamless digital experience that does not require additional authentication nor rely on simple transaction monitoring. ThreatMark goes beyond the industry standards to validate more than 25 million users and over 1 billion logins and transactions yearly.ThreatMark is shifting the paradigm in the digital world with advanced solutions complemented by a dedicated team of fraud specialists & cybersecurity experts working in our Security Operations Center (SOC), who vigilantly watch for new malicious activities throughout the digital landscape. Among various honors and industry recognition, ThreatMark has been recognized by Gartner as a Representative Vendor for the Online Fraud Detection area in its 2020 Market guide, named Deloitte’s Top Technology Fast 50 for CE; won 2019 AI Award – Company of the Year; and was awarded EY Entrepreneur of The Year for 2019.

The TRICAPITAL Syndicate is a business angel cohort of entrepreneurs, CEOs and business leaders who have founded, funded and built companies

Investment focus

Biotechnology, Software, Health Care
Funding Round, Seed, Series B
United Kingdom, France

Portfolio highlights

HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
Sellmyartworks — EzelDotz - Buy and Sell Contemporary Art Online | Art Marketplace. Curated collection of Sculptures, Limited Editions and Originals.
Heero Technologies — Heero Technologies, the leading independent energy platform for making net zero homes a reality

The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK.Typical funding requirements thatthe Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds.Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Estonia

Portfolio highlights

xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
illumion — Illumion develops high-throughput optical tools to accelerate battery material development
Wilder Sensing — Wilder Sensing analyses audio and other data sources to produce actionable insights into the status and trends of biodiversity on your site.

Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
United Kingdom, United States, Switzerland

Portfolio highlights

iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
Purespring Therapeutics — Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Resolution Therapeutics — Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases.

Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel...

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Pre-Seed
United Kingdom, Hungary

Portfolio highlights

Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
ViaNautis — Precision Solutions
Pencil Biosciences — Next Generation Genome Editing Tool

Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.

Investment focus

Software, E-Commerce, SaaS
Seed, Funding Round, Series A
United Kingdom, United States, Indonesia

Portfolio highlights

onHand — The volunteering and climate impact platform for businesses and individuals. Help your local communities and have global impact.
Lithium Salvage — Waste Lithium-ion Battery Recycling - A significant breakthrough in the recycling of ultra-high-value materials within waste Lithium-ion batteries.
Positive Support For You — Positive Support For You is a social enterprise dedicated to empowering adults with learning disabilities, providing tailored support to help them achieve greater independence, confidence, and inclusion in society.

We invest venture capital in to globally ambitious companies which have the potential to deliver a significant return to our investors

Investment focus

Health Care, Biotechnology, Manufacturing
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

novosound — Novosound is an award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.
Chromacity — Chromacity manufacture the next generation of ultrafast lasers. Discover our fixed wavelength femtosecond lasers and picosecond OPOs.
Biotangents — Biotangents develops veterinary diagnostic tests to detect infectious diseases in livestock (bovine viral diarrhoea (BVD), mastitis, bovine respiratory disease (BRD), brucellosis) using our highly adaptable molecular diagnostic technology, Moduleic Sensing.

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.

Investment focus

Artificial Intelligence, Software, Information Technology
Seed, Series A, Funding Round
United Kingdom, United States, Canada

Portfolio highlights

Cogna — Cogna offers an AI-powered SaaS platform that streamlines the integration of data across several business domains.
Formance — Numary makes it easy to build complex money-moving software with its open-source ledger & Numscript programming language.
Deblock — Forget your bank account: Get an IBAN, a Debit Card and a Non-custodial Crypto wallet. Deposit any crypto on your current account. Exchange Euro and Crypto without any limit.

Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.

Investment focus

Software, Artificial Intelligence, Information Technology
Pre-Seed, Seed, Funding Round
United Kingdom, United States, Canada

Portfolio highlights

Recfindr — Recfindr is a startup building a recruitment management system.
Implement AI — Implement AI provides managed AI agent solutions and teams of virtual workers via its AI Agent Platform, offering SMEs cost-effective, enterprise-grade solutions to amplify human potential, optimise productivity, and drive growth.
CareLoop Health — CareLoop, an innovation emerging from the University of Manchester, furnishes patients with digital support resources while simultaneously providing healthcare professionals with the means to monitor and track patient symptoms.

Founded in 2008, Par Equity is a venture capital firm that backs the most innovative, high growth technology companies in the North of the UK. Based in Edinburgh, Par invests across Northern England, Northern Ireland and Scotland.

Investment focus

Software, Information Technology, Health Care
Funding Round, Series A, Seed
United Kingdom, United States, Brazil

Portfolio highlights

Partful — Make sure customers get the right parts first time, every time with digital 3D parts catalogue software and digital work instructions.
Little Journey — Little Journey supports children and their families before, during and after healthcare interactions, reducing anxiety and improving health outcomes
Watercycle Technologies — Watercycle Technologies specialized in the development of high-yield, low-cost mineral extraction, and water treatment systems. Its core technology, capable of treating highly concentrated water, is an end-to-end solution encompassing mineral extraction, concentration, and crystallization.

Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom

Portfolio highlights

Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
PharmEnable — At PharmEnable Therapeutics we access the inaccessible. We are re-imagining small molecule therapeutics through AI.
Bastion Therapeutics — Bastion Therapeutics - Enhancing Tregs To Restore Balance In Inflammatory Disorders Treg cell therapy for inflammatory disorders and autoimmune diseases.

At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Seed
United Kingdom, United States, Ireland

Portfolio highlights

WorkL — Discover tools and insights to boost workplace happiness. For individuals and businesses, WorkL supports job satisfaction and employee engagement.
Invizius — Invizius is developing products to help patients on dialysis, cardiopulmonary bypass, ECMO and on other extra-corporeal treatments, to feel better, and suffer fewer complications.
Optalitix — Optalitix's data driven products and expertise allow you to move your models to the cloud and improve underwriting efficiency.

BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.

Investment focus

Software, Information Technology, Health Care
Funding Round, Series A, Private Equity
United Kingdom, Ireland, United States

Portfolio highlights

Sulmara — Innovation for a sustainable energy future | Sulmara
Besseges — ValvesTubesFittings.com launched in 2015 as the online arm of Besseges VTF and has become one of the leading online pipeline suppliers.
Miracle Design & Play — Miracle Design & Play specializes in designing and installing playgrounds for children.

We bring bold ideas to life to change the world for good.

Investment focus

Biotechnology, Medical Device, Medical
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
Radio Physics Solutions — Radio Physics Solutions is a security and investigation company that specializes in the fields of real-time concealed threat detection, Up to 30m Distance, autonomous, and unobtrusive. It specializes in providing early warning of threats concealed under peoples’ clothes, and so reduce the number of casualties caused by terrorists and criminalsglobally at schools, train stations, airports, government and military installations, tourist attractions and entertainment venues.Radio Physics Solutions was founded in 2009 and headquartered in Cambridgeshire, United Kingdom.

Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United Kingdom, United States, Ireland

Portfolio highlights

Forefront RF — Forefront RF tunable duplexer aims to expand the accessibility and global market reach of all mobile devices by simplifying RFFE design.
Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

Investment focus

Health Care, Software, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

CyberOwl — Helping maritime fleet operators gain visibility, cybersecurity and cyber compliance of shipboard systems with IMO 2021.
Optalitix — Optalitix's data driven products and expertise allow you to move your models to the cloud and improve underwriting efficiency.
onHand — The volunteering and climate impact platform for businesses and individuals. Help your local communities and have global impact.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
NovoLINC — NovoLINC is a pioneering startup that provides thermal interface solutions. It develops a distinctive system of nanostructured materials and a proprietary manufacturing process with the objective of transforming thermal management.
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

A new model for Venture Capital where every founder we back becomes a co-owner of the fund

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Series B
United Kingdom, Israel, United States

Portfolio highlights

Cradle — Design better proteins
Inversion — Inversion Space is a privately held company driven to change how humanity utilizes space. Its builds affordable, high cadence return vehicle for the commercial and defense industries.
Civic Marketplace — Civic Marketplace is a platform that simplifies purchasing decisions, helps agencies make efficient, informed choices, and boosts local economic growth by providing access and opportunities to historically underutilized businesses.

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Information Technology, Manufacturing
Funding Round, Series A, Seed
United Kingdom, United States

Portfolio highlights

Netacea — Netacea takes a smarter approach to bot management. Intent Analytics™ powered by machine learning quickly and accurately distinguishes bots from humans to protect websites, mobile apps and APIs from automated threats while prioritising genuine users. Actionable intelligence with data-rich visualisations empowers you to make informed decisions aboutyour traffic. The Netacea approach offers incredible speed, accuracy and transparency, solving the growing problem of credential stuffing and account takeover at scale. The technology is designed to complement existing controls such as WAF rulesets, rate limiting and threat databases to provide a deep analysis of all website visitors, actionable intelligence and real-time threat.The Netacea approach continuously monitors your web traffic to pinpoint the difference in automated bot activity vs genuine visitors, keeping you ahead of evolving bot threats. Choose to automatically block, redirect or challenge automated attacks in real-time, or receive alerts notifying you of potential threats. With access to rich dashboards and data, you can easily identify and stop account takeover attempts early in the attack chain.Learn more at www.netacea.com
Semble — The integrated clinical system for managing your patients' medical data and admin tasks.
Locate Bio — Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs.

IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Funding Round
United Kingdom, United States, The Netherlands

Portfolio highlights

Mindgard — Mindgard is an AI security company that helps enterprise to test, detect, and respond to cyber threats against their AI models.Given that businesses are increasingly focused on offering AI-driven services such as LLMs, securing this new way of conducting business is equally important. Mindgard ensures that your business can safely and securelymove into the new AI world and continue to protect your digital assets, brand and reputation.Our platform enables enterprise customers to determine, detect, and remediate against any adversarial attack vulnerabilities within all their AI models. This answers the “What is my AI risk?” and “How do I mitigate my AI risk?” questions that currently cannot be answered using traditional Cyber Security platforms. By designing our platform from the ground up to integrate with existing AI and Cyber Security operational tooling, Mindgard can be seamlessly added to your organization, providing repeatable and automated AI model vulnerability testing.The Mindgard platform has been in development for over 4 years based on cutting edge PhD-led, AI & cyber security research, also used by the global Intelligence Community. As well as providing a library of adversarial attacks based on deep research, leveraging our platform that can automate repeated security testing, detection, and response across the entire AI estate. By leveraging the Mindgard platform, our clients free up precious AI and cyber security resources and at the same time understand, detect, and mitigate risks across their entire AI model portfolio, which currently takes too long and is too expensive. Our platform ensures that business can rapidly embrace LLMs and other AI technologies whilst protecting their digital assets, brand, and reputation within the new AI world.
IONATE — IONATE Ltd. is a technology company developing next-generation Hybrid Intelligent Transformers.
Mindgard Ltd — Mindgard Ltd specializes in providing comprehensive AI security solutions to enterprises. Our operations center around a sophisticated platform designed to determine, detect, and remediate adversarial attack vulnerabilities within AI models. The platform is built on over four years of PhD-led research in AI and cyber security, ensuring advancedprotection that traditional Cyber Security platforms cannot offer.Our platform integrates seamlessly with existing AI and Cyber Security tools, enabling automated and repeatable vulnerability testing across the entire AI estate. This integration allows enterprises to efficiently assess and mitigate risks, optimizing their AI and cyber security resources.Key operational features include: - Automated Security Testing: Utilizing a library of adversarial attacks, our platform conducts thorough and repeated security tests to identify vulnerabilities. - Detection and Response: The platform continuously monitors AI models for threats and provides rapid detection and response capabilities to neutralize potential attacks. - Seamless Integration: Designed for compatibility with existing operational tools, our platform can be easily incorporated into current security infrastructures.Mindgard Ltd's operations ensure that businesses can securely adopt and innovate with AI technologies while protecting their digital assets, brand, and reputation in the evolving AI landscape.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

RenBio — RenBio develops antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases. RenBio's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint and antibody factory.
Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

YFM Equity Partners is an independent private equity business owned by its senior management and investment team. They invest up to £10 million of equity through offices in Leeds, London, Manchester, Birmingham and Sheffield.

Investment focus

Software, Information Technology, Biotechnology
Funding Round, Private Equity, Series A
United Kingdom, United States, Belgium

Portfolio highlights

Fuuse — Fuuse is an electric vehicle charge point management system that enables your chargers to deliver more for you and your drivers.
Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
Psychology Tools — Psychology Tools publishes evidence-based resources to improve your therapy and save you time. Download CBT worksheets.

Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today

Investment focus

Software, Artificial Intelligence, Information Technology
Series B, Seed, Series A
United Kingdom, United States, Spain

Portfolio highlights

Natrox — Inotec AMD is a wound-care company that has developed Natrox:tm:, a device that produces a continuous flow of humidified oxygen and directs it to a specially-designed dressing, allowing oxygen to constantly refresh the wound.NATROX:tm: is a battery-powered medical device that produces a continuous flow of pure humidified oxygen from air anddirects it through a fine tube to a specially-designed Oxygen Delivery System (ODS), allowing the oxygen to constantly refresh the wound while allowing free passage of wound fluids (exudate) to pass away from the wound surface for absorption and retention in the normal way.
Refute — Refute identifies and addresses misinformation on behalf of there businesses.
iPronics — iPronics develops the innovative concepts of general-purpose integrated programmable photonic systems.

Meltwind Advisory.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Natrox — Inotec AMD is a wound-care company that has developed Natrox:tm:, a device that produces a continuous flow of humidified oxygen and directs it to a specially-designed dressing, allowing oxygen to constantly refresh the wound.NATROX:tm: is a battery-powered medical device that produces a continuous flow of pure humidified oxygen from air anddirects it through a fine tube to a specially-designed Oxygen Delivery System (ODS), allowing the oxygen to constantly refresh the wound while allowing free passage of wound fluids (exudate) to pass away from the wound surface for absorption and retention in the normal way.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.

Longwall Ventures invests in innovative, UK based, early stage companies in the healthcare, science and engineering sectors

Investment focus

Biotechnology, Medical Device, Health Care
Funding Round, Seed, Series A
United Kingdom, Germany, Philippines

Portfolio highlights

Biofidelity — Unleashing the potential of genomics to transform the world we live in through transformational technologies that remove the noise from genomic analysis.
Wayland Additive — Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.
Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

A corporate venture investment company focussed on investing in mid to late stage clinical stage therapeutics development companies in North America and Europe

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
United Kingdom, Switzerland, United States

Portfolio highlights

Amlo Biosciences — From ground-breaking research to revolutionary prognostics and diagnostics AMLo Biosciences is translating ground-breaking research in cancer biomarkers int ...
Acousia Therapeutics — Acousia Therapeutics GmbH is a privately held biotech company based in Tübingen, Germany. Acousia has experience and expertise in identifying and developing small molecule drug candidates for the treatment of hearing loss.Sensory hair cells are the key cells for hearing in the inner ear. Acousia`s approach will help to replace lost hair cells bycellular regeneration originating from supporting cells.ASpherecousia is developing drugs for local application, which will restore hearing in patients who have lost their hearing ability induced by various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, these therapies will have the potential to treat the age-related decrease in hearing capacity.
Spiral Therapeutics — Spiral Therapeutics is a clinical stage pharmaceutical company delivering novel therapies for hearing loss. Through the use proprietary therapeutics and drug delivery technologies, Spiral is building a pipeline of advanced therapies in a field with large unmet needs and no approved therapies. Spiral’s lead candidate, LPT99, reached the clinic inDecember 2018. Spiral was launched in early 2016 and is headquartered in Brisbane, CA.

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Sudo Biosciences — Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class.
LOQUS23 THERAPEUTICS — LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases